Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma

Taussig, Matthew D.; Koran, Mary Ellen; Mouli, S.; Ahmad, Asma; Geevarghese, Sunil K.; Baker, Jennifer; Lipnik, Andrew J.; Banovac, Fil; Brown, Daniel B.

doi:10.1016/j.hpb.2017.01.013

Cited by 30 publications

(20 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…79,80 Moreover, an elevated NLR also seems to have prognostic significance in those undergoing trans-arterial chemoembolization (TACE) therapy. 81,82 It should also be noted that longer operating times 84 and worse OS and DFS 85 (Table 3). Some studies have also evaluated the role of inflammation-based scores in those undergoing orthotopic liver transplantation (OLT), with OS nearing 75% after 4 years, 86 and tumour recurrence appearing in 8%-15% of all graft recipients that fulfilled the Milan criteria.…”

Section: Inflammation-based Prognostic Indices In the Curative Settingmentioning

confidence: 99%

“…Likewise, deterioration of NLR following RFA may predict earlier recurrence and associated mortality . Moreover, an elevated NLR also seems to have prognostic significance in those undergoing trans‐arterial chemoembolization (TACE) therapy . It should also be noted that lower cut‐off values of NLR were used for prognostic stratification in early stage HCC compared to advanced disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

Sanghera

Teh

Pinato

2019

Liver International

View full text Add to dashboard Cite

The pathogenesis of hepatocellular carcinoma (HCC) strongly relates to inflammation, with chronic up‐regulation of pro‐inflammatory mediators standing as a potential unifying mechanism that underscores the origin and progression of HCC independent of aetiology. Activation of the diverse pro‐inflammatory mediators either within the tumour or its microenvironment is part of an active cross‐talk between the progressive HCC and the host, which is known to influence clinical outcomes including recurrence after radical treatments and long‐term survival. A number of clinical biomarkers to measure the severity of cancer‐related inflammation are now available, most of which emerge from routine blood parameters including neutrophil, lymphocyte, platelet counts, as well as albuminaemia and C‐reactive protein levels. In this review, we summarise the body of evidence supporting the biologic qualification of inflammation‐based scores in HCC and review their potential in facilitating the prognostic assessment and treatment allocation in the individual patient. We also discuss the evidence to suggest modulation of tumour‐promoting inflammation may act as a source of novel therapeutic strategies in liver cancer.

show abstract

Section: Inflammation-based Prognostic Indices In the Curative Settingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

Sanghera

Teh

Pinato

2019

Liver International

View full text Add to dashboard Cite

show abstract

“…NLR has been investigated in regard to different embolisation and ablation techniques. High NLR (>3) predicted significantly worse treatment results (p = 0.014) and early disease progression (p < 0.0001) in 86 treatment-naive patients subjected to arterial chemoembolisation or radioembolisation [55]. Elevated pre-treatment NLR (>1.85) was associated with overall survival and disease-free survival in 178 HCC patients subjected to transcatheter arterial chemoembolisation (TACE).…”

Section: Neutrophil-to-lymphocyte Ratio In Hcc Patients Undergoing Tumentioning

confidence: 99%

Innovative Blood Tests for Hepatocellular Carcinoma: Liquid Biopsy and Evaluation of Systemic Inflammatory Reaction

Štrumfa¹,

Mezale²,

Strumfs³

et al. 2018

Hepatocellular Carcinoma - Advances in Diagnosis and Treatment

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is an aggressive tumour associated with dismal prognosis. To improve the outcome, early diagnostics is important. At present, classical HCC diagnostics is based on evaluation of risk factors, surveillance in cirrhotic patients, preference for non-invasive diagnosis by computed tomography or magnetic resonance imaging and biopsy confirmation in controversial cases. However, ambiguous radiological presentation, biopsy-related complications or insufficient representation of the pathology in the tissue core are well-known problems. Panel assessment of microRNAs has diagnostic and prognostic value; thus, in future, microRNA-based liquid biopsy could partially reduce the need for core biopsies. Systemic inflammatory reaction (SIR), characterised mainly by neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and Glasgow prognostic score, may have prognostic value and can be incorporated in criteria for certain treatment approaches, e.g., becoming an adjunct to Milan criteria. Thus, innovations in HCC diagnostics are expected in the field of miRNA-based liquid biopsy for diagnosis/prognosis and SIR for prognosis/selection of treatment.

show abstract

“…He et al 10) reported the usefulness of NLR and platelets to lymphocytes ratio (PLR) after transarterial chemoembolization. Taussig et al also reported 11) that NLR predicted disease progression following intra-arterial therapy of HCC. In the present study, NLR was good biomarkers for predicting long-term outcomes after Hx.…”

Section: Discussionmentioning

confidence: 94%

Preoperative prognostic nutritional index predicts both short and long-term outcomes after liver resection for hepatocellular carcinoma.

Saito

Imura

Morine

et al. 2019

Preprint

View full text Add to dashboard Cite

Background The aim of this study was to investigate the prognostic significance of the prognostic nutritional index (PNI) for both short and long term outcomes after liver resection for hepatocellular carcinoma (HCC). Methods 162 (without any previous treatment) of 229 surgically treated HCC patients were retrospectively analyzed. The cut off value of the preoperative PNI was 45.0. Patients were divided into two groups, PNI low (n=76) and high (n=86) group. Results Among some immune parameters such as PNI, neutrophil to lymphocyte ratio (NLR) and aspartate aminotransferase (AST) to lymphocyte ratio (ALRI), PNI had most reliable parameters in terms with prediction of both short and long term outcomes. Preoperative PNI tended to correlate with low skeletal muscle mass (SMM). In short term outcomes, PNI low group were more likely to have postoperative complications. The disease-free survival rate in PNI low group was significantly worse than that in the PNI high group (20.5 vs. 48.7 %, 5 year SR, p=0.03). On multivariate analysis, Low PNI was an independent prognostic factor for disease free survival (HR 1.65, p= 0.04). Conclusions The preoperative PNI was the most significant prognostic factor for evaluating both short and long-term outcomes after liver resection for HCC.

show abstract

Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma

Abstract: NLR may be a serologic biomarker of early progressive disease after intra-arterial therapy of HCC. Future research should focus on outcomes by treatment type or potentially combining arterial therapies with ablation and/or targeted biologic agents.

Cited by 30 publications

References 34 publications

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

The systemic inflammatory response as a source of biomarkers and therapeutic targets in hepatocellular carcinoma

Innovative Blood Tests for Hepatocellular Carcinoma: Liquid Biopsy and Evaluation of Systemic Inflammatory Reaction

Preoperative prognostic nutritional index predicts both short and long-term outcomes after liver resection for hepatocellular carcinoma.

Contact Info

Product

Resources

About